Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kontafarma China HoldingsHKSE:01312 -3.45% Dividend Yield % is 0.00% as of Aug. 07, 2026. The stock has 3 warning signs investors should review. Among 513 Drug Manufacturers companies, Kontafarma China Holdings ranks worse than 194931.58% on this metric.
The historical rank and industry rank for Kontafarma China Holdings's Dividend Yield % or its related term are showing as below:
HKSE:01312's Dividend Yield % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.98 * Ranked among companies with meaningful Dividend Yield % only.
Kontafarma China Holdings (HKSE:01312) Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Kontafarma China Holdings's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kontafarma China Holdings Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kontafarma China Holdings's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Kontafarma China Holdings's Dividend Yield % falls into.
Kontafarma China Holdings (HKSE:01312) has a Dividend Yield % of 0.00% as of Aug. 07, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Kontafarma China Holdings and its competitors. According to the industry distribution chart, Kontafarma China Holdings ranks #999999 out of 513 companies in the Drug Manufacturers industry.
Is Kontafarma China Holdings' Dividend Yield % too high?
Kontafarma China Holdings' current Dividend Yield % is 0.00%. Based on the distribution chart, Kontafarma China Holdings ranks #999999 out of 513 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Kontafarma China Holdings' Dividend Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Kontafarma China Holdings ranks #999999 out of 513 companies for Dividend Yield %. This places Kontafarma China Holdings in the lower half of its industry. The industry median Dividend Yield % is 1.98. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Drug Manufacturers company?
The median Dividend Yield % among Drug Manufacturers companies is 1.98, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Kontafarma China Holdings and its competitors. For the Drug Manufacturers industry, the median Dividend Yield % is 1.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kontafarma China Holdings's current Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kontafarma China Holdings stock overvalued right now?
Based on GuruFocus' analysis, Kontafarma China Holdings (HKSE:01312) is currently considered Possible Value Trap. The stock's GF Value™ is HK$0.04, compared to a current price of HK$0.03 — trading 30% below its estimated fair value. The current Dividend Yield % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Kontafarma China Holdings (HKSE:01312), the current Dividend Yield % is 0.00% as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kontafarma China Holdings Ltd and its subsidiaries are principally engaged in the pharmaceutical and fitness business. The Group manufactures and sells prescription drugs, including chemical drugs, traditional Chinese medicine prescriptions, active pharmaceutical ingredients, and API intermediates in China, and operates fitness centres, provides fitness and health consultation services, and operates a franchise business for royalty fee income. Its segments are the pharmaceutical business, which generates maximum revenue, and the fitness business. The Group operates in Mainland China, Singapore, Taiwan, and other regions, with maximum revenue from Mainland China.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01312 has been successfully added to your 
